CARBON: UAB Cardiovascular Research Biobank

Last updated: July 1, 2025
Sponsor: University of Alabama at Birmingham
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetic Vitreous Hemorrhage

Diabetic Foot Ulcers

Williams Syndrome

Treatment

N/A

Clinical Study ID

NCT05067231
IRB - 300007834
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers undertaking a wide range of medical research.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age more than or equal to 18

Exclusion

Exclusion Criteria:

  • Age <18, at screening

  • Employees or students associated with the Division of Cardiovascular Disease at UABwill not be recruited due to their vulnerable status and susceptibility to coercion.

  • Women who are pregnant or who can become pregnant and not practicing an acceptablemethod of birth control.

Study Design

Total Participants: 500
Study Start date:
January 01, 2022
Estimated Completion Date:
January 01, 2026

Study Description

The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains pertinent genetic, health, and biological samples such as blood derived from a large-scale population. Researchers may use disease correlates and predictors identified from the genetic, health, and personal information contained in the Biobank as a resource to investigate cardiovascular disease, hypertension, diabetes, and a myriad of other disorders. Through these studies, researchers may identify the progression of risk factors in certain diseases and help develop novel strategies to detect, treat, or prevent such diseases. In addition, the Biobank serves as a valuable tool to assess how certain treatments may respond differently to individuals as a result of genotypic differences.

The investigators have demonstrated that lower natriuretic peptide (NP) levels are associated with a decreased insulin sensitivity and have a causal role in the development of diabetes and have also shown that certain populations, such as African Americans, have relatively low NP levels, which may contribute to their underlying risk for insulin resistance. Since NPs play an important role in the regulation of insulin sensitivity, one can infer that relatively low NP levels are an important biological contributor to the high prevalence rates of cardiometabolic disease in African Americans. The Biobank will contain genetic information concerning the presence of gene variants that encode NPs.

Connect with a study center

  • University of Alabama at Birmingham

    Birmingham, Alabama 35294
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.